OR WAIT null SECS
September 15, 2021
Article
Multiple PSMA-PET imaging agents are approved by the FDA for use in prostate cancer.
September 01, 2021
"This is the first time that I have seen such impressive responses with an immunotherapy product. The responses of my patients in the trial are far beyond my expectations," said study investigator Susan F. Slovin, MD, PhD.
August 25, 2021
The theranostic 64/67Cu SAR-bisPSMA combines the PSMA PET imaging product 64Cu-SAR-bisPSMA and the PSMA targeted therapy 67Cu-SAR-bisPSMA.
August 24, 2021
Video
Susan F. Slovin, MD, PhD, highlights 177Lu-PSMA-617 and the radiopharmaceutical revolution in metastatic castration-resistant prostate cancer.
August 16, 2021
Preclinical data have provided further evidence that adding the novel radiosensitizer idronoxil to 177Lu-PSMA-617 may improve survival in patients with metastatic castration-resistant prostate cancer.
August 13, 2021
“Targeted ligand therapy is extremely exciting,” says Ketan K. Badani, MD.
August 11, 2021
The pivotal phase 3 SPLASH study is exploring the novel PSMA-targeted therapy PNT2002 in patients with metastatic castration-resistant prostate cancer.
August 09, 2021
ARX517 is being explored in patients with prostate cancer and other PSMA-expressing solid tumors.
August 05, 2021
Patient tumors must express PSMA as identified by 68Ga-PSMA-11 or 18F-DCFPyl PSMA PET/CT scanning.
July 28, 2021
